Expertise in
1
conditions

Patricia Roxburgh

Glasgow, SCT, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Glasgow, SCT, GB 
OverviewLocationsClinical Research

Overview

Patricia Roxburgh practices in Glasgow, United Kingdom. Ms. Roxburgh is highly rated in 1 condition, according to our data. Her top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer.

Her clinical research consists of co-authoring 31 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Glasgow, SCT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Enrollment Status: Recruiting
Publish Date: January 24, 2025
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Terminated
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

31 Total Publications

Controversies in the management of serous borderline tumors and low-grade serous ovarian cancer.
Controversies in the management of serous borderline tumors and low-grade serous ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: January 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Roxburgh's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile